Candel Reports Positive Phase 3 Follow-Up Data For Aglatimagene In Prostate Cancer

Candel Therapeutics reported positive Phase 3 results for Aglatimagene in prostate cancer, reinforcing the therapy's clinical potential. The update is a meaningful catalyst for the clinical-stage biotech and supports the company's fundamental outlook, though no approval or commercial figures were disclosed. The news is likely supportive for CADL shares and could move the stock modestly on the positive trial readout.

Analysis

Candel Therapeutics reported positive Phase 3 results for Aglatimagene in prostate cancer, reinforcing the therapy's clinical potential. The update is a meaningful catalyst for the clinical-stage biotech and supports the company's fundamental outlook, though no approval or commercial figures were disclosed. The news is likely supportive for CADL shares and could move the stock modestly on the positive trial readout.